AbbVie Inc. — Director's Dealing 2022

Mar 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-03-01

Reporting Person: Gosebruch Henry O (EVP, Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock, $0.01 par value	S	15733	$146.8105	Disposed	25890	Direct
2022-03-01	Common Stock, $0.01 par value	S	5167	$147.6015	Disposed	20723	Direct
2022-03-01	Common Stock, $0.01 par value	S	4000	$148.7060	Disposed	16723	Direct
2022-03-01	Common Stock, $0.01 par value	S	100	$149.381	Disposed	16623	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.01 par value	78500	Indirect
Common Stock, $0.01 par value	3457	Indirect

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.

F6: Balance in AbbVie Savings program as of January 31, 2022.